Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 70Breast Neoplasms 64Neoplasms 35Carcinoma, Non-Small-Cell Lung 29Neoplasm Metastasis 20Triple Negative Breast Neoplasms 18Lung Neoplasms 13Ovarian Neoplasms 12Adenocarcinoma 12Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Melanoma 10Head and Neck Neoplasms 8Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Esophageal Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Digestive System Neoplasms 5Colorectal Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Prostatic Neoplasms 4Pancreatic Diseases 4Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Endocrine Gland Neoplasms 4

Interventions

Gemcitabine 1Docetaxel 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Histiocytoma × Albumin-Bound Paclitaxel × Clear all
NCT01962103 2019-12-27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Celgene

Phase 1/2 Completed
107 enrolled 42 charts
CNSDermatologicSarcoma

Fibrosarcoma, Melanoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Dermatofibrosarcoma, Histiocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡